Felstead S
Clinical and Safety Regulatory Affairs, PFYZER Central Research, Sandwich, UK.
Pathol Biol (Paris). 1995 Jun;43(6):512-4.
Pre clinical work in vivo and in vitro have suggested that azithromycin has a low potential for significant drug interactions. Clinical studies conducted thus far have generated results in accordance with the preclinical science [6]. Direct comparisons with the most modern macrolides have been published and evidence suggests that azithromycin is likely to be associated with fewer significant drug interactions. However, as a final point, I wish to point out that proof of an absolute negative is not possible and therefore in any patient, on multiple medication with adverse findings, a drug interaction should be considered as part of the differential diagnosis.
体内和体外的临床前研究表明，阿奇霉素发生显著药物相互作用的可能性较低。迄今为止进行的临床研究结果与临床前科学一致[6]。已发表了与最新型大环内酯类药物的直接比较，证据表明阿奇霉素可能与较少的显著药物相互作用相关。然而，最后我想指出，不可能有绝对阴性的证据，因此在任何服用多种药物且有不良发现的患者中，药物相互作用应被视为鉴别诊断的一部分。
